Search Clinical Trials in the EU

Duration

11-15 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

221-240 of 306 trials

Congenital Hyperinsulinism: HM15136 Treatment Study

We are evaluating a new treatment for children with congenital hyperinsulinism to see if it is safe and helps reduce low blood sugar events. This study includes children aged 2 years and older.

Congenital Hyperinsulinism≤3 monthsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementEndocrinologyPediatrics

Epithelioid Malignant Pleural Mesothelioma: Atezolizumab and WT1/DC Vaccine

We are studying the safety and effectiveness of adding a new treatment to standard chemotherapy for patients with epithelioid malignant pleural mesothelioma. This trial aims to see if the combination improves treatment outcomes.

Malignant Pleural Mesothelioma6-12 monthsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncologyPulmonology

Schizophrenia: Biomarkers for Clozapine Response

We are investigating whether specific biomarkers can help predict how well individuals with schizophrenia respond to clozapine. This research may lead to more tailored treatments for those who need them.

Schizophrenia≤3 monthsMonitoring phase (IV)11-15 visits No Placebo Standard MedicinesNeurologyPsychiatry

DENOCHARCOT Trial: DENOsumab for Charcot Foot in Diabetes

We are studying whether DENOsumab can effectively treat acute Charcot foot in people with diabetes. This trial compares the medication to a placebo to assess its impact on health outcomes.

Diabetic Charcot Foot1-2 yearsMonitoring phase (IV)11-15 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementEndocrinologyOrthopedics and Traumatology

CIDP: NVG-2089 Treatment Study

We are evaluating the safety and effectiveness of NVG-2089 for individuals with Chronic Inflammatory Demyelinating Polyneuropathy. This study aims to find out if it can help improve symptoms and overall health.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Efficacy phase (II)11-15 visits No Placebo Investigational Medicines Cost ReimbursementNeurology

Advanced Neuroendocrine Carcinomas: Enfortumab-Vedotin Study

We are studying a new treatment for patients with advanced Neuroendocrine Carcinomas who cannot use standard chemotherapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesEndocrinologyOncology

Kidney Disease: VX-147 Study for APOL1 Variants

We are testing the safety and effectiveness of VX-147 in adults and children with APOL1-mediated proteinuric kidney disease. The study aims to see if this treatment can improve kidney function and reduce related health risks.

APOL1-mediated Proteinuric Kidney Disease>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Investigational Medicines Cost Reimbursement Partially RemoteNephrology

Colorectal Cancer: Temozolomide and Irinotecan Treatment

We are studying a combination of temozolomide and irinotecan for patients with specific colorectal cancer characteristics after standard chemotherapy. The goal is to see if this treatment helps eliminate remaining cancer cells and improves survival.

Stage II/III Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesOncology

Chronic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with chronic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Chronic Migraine6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Partially RemoteNeurology

Episodic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with episodic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Episodic Migraine6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Partially RemoteNeurology

C3 Glomerulopathy: Aliskiren vs. Enalapril

We are studying whether the medication aliskiren can improve kidney function in people with C3 glomerulopathy compared to the standard treatment, enalapril. This trial aims to assess its safety and effectiveness in reducing kidney disease markers.

C3 Glomerulopathy>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard MedicinesInfectious DiseasesNephrology

Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

Paroxysmal Nocturnal Hemoglobinuria (PNH)6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteHematologyInternal Medicine

Efgartigimod for Early Treatment of Generalized Myasthenia Gravis

We are studying whether efgartigimod can improve daily activities and quality of life for patients with generalized myasthenia gravis and specific antibodies. This trial will help us understand its effectiveness and tolerability as an early treatment option.

Generalized Myasthenia Gravis6-12 monthsMonitoring phase (IV)11-15 visits No Placebo Standard Medicines Partially RemoteNeurology

Multiple Myeloma: Belantamab Mafodotin vs. Daratumumab

We are studying a new treatment combination for people with newly diagnosed multiple myeloma who cannot have stem cell transplants. The goal is to see if it works better and is safer than the current standard treatment.

Multiple MyelomaConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

Oropharyngeal Cancer: Comparing Treatment Options

We are studying different treatment regimens for patients with intermediate and high-risk oropharyngeal cancer to see if they improve survival and quality of life. This trial also aims to evaluate side effects and the cost-effectiveness of these treatments.

Oropharyngeal Cancer>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesOncology

Immunotherapy for Cutaneous Squamous Cell Carcinoma

We are studying whether immunotherapy can help patients with skin cancer achieve remission without surgery or radiation. This trial aims to assess the treatment's effectiveness and safety over time.

Skin Cancer (Cutaneous Squamous Cell Carcinoma)>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesDermatologyOncology

Acute Demyelinating Syndromes in Children: Azathioprine vs. Rituximab

We are studying whether starting treatment immediately with azathioprine or rituximab helps children with anti-MOG antibodies better than delaying treatment until a second attack. The goal is to see which method reduces relapses and improves health outcomes.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyRheumatology

Sjögren’s Disease: Sibeprenlimab Treatment Study

We are investigating whether Sibeprenlimab can improve symptoms in people with Sjögren’s Disease compared to a placebo. The study will also look at the safety and tolerability of this new treatment.

Sjögren's Disease1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementInfectious DiseasesRheumatology

Alzheimer’s Disease: KarXT for Psychosis

We are testing a new treatment called KarXT for people with psychosis associated with Alzheimer’s disease. The study aims to see if it can reduce symptoms like hallucinations and delusions compared to a placebo.

Psychosis Associated with Alzheimer's Disease3-6 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPsychiatry

Stage IIIA/B NSCLC: New Immunotherapy and Chemotherapy Approach

We are studying a new treatment combining immunotherapy and chemotherapy for patients with resectable stage IIIA/B non-small cell lung cancer. The trial aims to see if this approach improves survival and quality of life compared to standard treatments.

Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesOncology

Search Clinical Trials in the European Union